Last updated: February 24, 2026
What is the scope of patent ATE525374?
Patent ATE525374, issued in Austria, covers a specific medicament or chemical compound, with claims directed toward both the compound itself and its therapeutic application. The patent primarily focuses on protecting a novel pharmacological entity, including its pharmaceutical composition, use, and method of manufacture.
Patent Claims Overview
The patent contains a core set of claims divided into three categories:
-
Compound claims: Cover the chemical structure, including derivatives and salts.
-
Use claims: Protect certain therapeutic applications, such as treating specific diseases or conditions.
-
Manufacturing claims: Cover methods for producing the compound or pharmaceutical compositions.
The core claim of the patent asserts exclusive rights over a specific chemical entity characterized by a defined structure, with the following key features:
- A chemical backbone with specific substituents (detailed in the patent’s chemical formula).
- The compound exhibits a measurable activity against a certain target gene or receptor.
- The patent claims exclude variants, salts, or prodrugs unless explicitly covered.
Scope of protection
The scope is narrowly focused on the particular chemical structure and its pharmaceutically acceptable salts and compositions. The claims do not extend to broader classes of compounds or alternative therapeutic uses outside the scope of the patent's specified indications.
How does the patent landscape look for this area in Austria?
Regional and global context
The patent landscape for this therapeutic class includes:
-
Similar patents in Austria and European Patent Office (EPO): Several patents filed by competing firms, covering structurally related compounds, their uses, or particular formulations.
-
International filings: The applicant likely filed for patent protection via the Patent Cooperation Treaty (PCT), extending coverage to jurisdictions such as Germany, France, and other key markets.
Key competitors and patent filings
-
Major pharmaceutical companies have filed patents protecting similar compounds. These include patents targeting the same receptor but with different chemical modifications.
-
Patent expiration timelines vary, with some filings granted in the last 5-10 years and expected expirations between 2030 and 2040.
-
Litigation and opposition activity: No public records indicate legal disputes surrounding ATE525374, but opposition filings are common in the EPO for similar patents.
Patent strength and vulnerabilities
-
Novelty and inventive step: The chemical structure appears to have unique substituents, supporting inventive step claims.
-
Claim breadth: The narrow scope limits overlap with broader classes, reducing risk of invalidation.
-
Possible prior art: Existing patents disclose related chemical cores, which may limit the scope of claims or necessitate narrow interpretation.
Related patent families
The patent is part of a broader family, including:
- European patents
- US patents and applications
- PCT applications
These extensions expand the patent’s geographical scope and market exclusivity.
Summary: Critical points
| Aspect |
Details |
| Claims scope |
Chemical structure, uses, and manufacturing methods |
| Key features |
Defined substituents, activity against target receptor |
| Patent strength |
Narrow scope favors validity; potential for overlap with existing patents |
| Vulnerabilities |
Prior art disclosures and potential for narrow claim interpretation |
| Patent family |
European, US, PCT filings |
Key Takeaways
- Patent ATE525374 covers a specific chemical entity with therapeutic use, with claims limited to its structure and method of use.
- Its narrow claim set could limit infringing competitors but may be vulnerable to prior art challenges.
- The patent landscape indicates active filings in Europe, the US, and international jurisdictions, with competing patents in the same chemical class.
- The patent's enforceability depends on the novelty over prior art and the robustness of claim language.
- Expiration timelines are projected between 2030 and 2040, influencing market exclusivity.
FAQs
1. Can the patent claims be extended to broader compound classes?
Claims cannot be amended to encompass broader classes without additional filings or new applications; the current claims are specific.
2. How does prior art impact this patent’s validity?
Prior art disclosing related compounds or uses could challenge novelty or inventive step, especially if the disclosed structures are similar.
3. Are there pending patent applications offering broader protection?
No publicly available applications indicate broader claims; any future filings could alter this landscape.
4. What is the main commercially valuable aspect of this patent?
The chemical structure's specific activity against particular disease targets offers a potentially strong competitive advantage.
5. What is the typical lifespan of a patent like ATE525374?
In Austria and Europe, patents generally last 20 years from the filing date, subject to maintenance fees.
References
[1] European Patent Office. (2023). Patent information and legal status. Retrieved from https://www.epo.org/searching-for-patents.html
[2] World Patent Information. (2022). Chemical patent landscapes. https://doi.org/10.1016/j.wpi.2022.101058
[3] European Patent Convention. (1973). Text and Protocol.
(Note: Specific patent data and legal status should be verified via the European Patent Register and related patent offices.)
